Who Is Sean Bohen?
This article was originally published in Scrip
Executive Summary
Respected American scientist Sean Bohen made headlines Monday with news he will move to AstraZeneca PLC on September 15 from Genentech Inc., the biologics unit of Roche Holding AG where he has been senior vice president in charge of early clinical development. The California-based division, known in the jargon as gRED, has notched up a legendary string of cancer drug successes, and Bohen played a notable part in many of them.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.